Summit Therapeutics Inc. · NASDAQ:SMMT
Summit Therapeutics — Q4 2024 Earnings Presentation
13 slides from Summit Therapeutics's earnings presentation, Feb 24, 2025
Slide 1: Summit Therapeutics Q4 & YE 2024 Earnings Call
Summit Therapeutics Q4 & YE 2024 Earnings Call February 24, 2025 9:00am ET
Slide 2: Forward Looking Statement
Forward Looking Statement Any statements in this presentation about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s par
Slide 3: Q4 2024 & Recent Highlights
Q4 2024 & Recent Highlights Ivonescimab in 2024: 2,300+ Completed enrollment, Activation has begun for Total patients treated Fast Track designation, the initial U.S. trial sites in clinical trials 1 data expected mid-2025 14 z Publications in 2024 in 7 tumor types 2 5 Trial expanded to include non-
Slide 4: Ivonescimab Pipeline
Ivonescimab Pipeline Conducted in China Planned and Ongoing Studies Fully Sponsored and Managed by Akeso Sponsored by Summit Therapeutics* Phase III Phase III 2L+ NSCLC: 2L+ NSCLC: 1L NSCLC: 1L NSCLC: 1L NSCLC: 1L NSCLC: 1L R/M HNSCC: Expanding CDP 1L Biliary Tract: Further Announcements Planned in
Slide 5: Ivonescimab Catalysts in 2025-2026
Ivonescimab Catalysts Global in 2025-2026 China First Global Clinical Trial Enrollment Complete1 Results in Mid-2025 Expanding our Global Clinical Trial Clinical Development Plan2 Data Readouts Beyond NSCLC NSCLC and Beyond Investigator Sponsored Initiation of Additional Trials Activating3 Phase III
Slide 6: Ivonescimab + Chemo vs. Pembrolizumab + Chemo
Ivonescimab + Chemo vs. Pembrolizumab + Chemo Summit Sponsored Study Randomized, Double-blind, Phase III Study 1L NSCLC: PD-L1 All-Comers* NCT05899608 Non-Squamous OR Squamous Maintenance Key Inclusion Non-Squamous: • 1L squamous or Ivonescimab + Safety and Survival Follow-up Ivonescimab + Ivonescim
Slide 7: Monotherapy Ivonescimab vs. Pembrolizumab
Monotherapy Ivonescimab vs. Pembrolizumab Summit Sponsored Study Randomized, Double-blind, Phase III Study 1L NSCLC with PD-L1 High Expression NCT067675141 Key Inclusion • 1L squamous or Safety and Survival Follow-up Ivonescimab non-squamous 20 mg/kg Q3W Treatment Until Randomization metastatic NSCL
Slide 8: Ivonescimab Opportunity Goes Beyond Checkpoint Inhibitors
Ivonescimab Clinical Trials Ivonescimab Opportunity Goes Beyond Checkpoint Inhibitors (CPI) 2028 Estimated $90B+ CPI TAM 2 $20B+ NSCLC CPI TAM2,3 50+ Approved Indications for 1 PD-(L)1 & VEGF Therapies Approved Anti-VEGF Therapies Approved Anti PD-(L)1 Therapies Approved Anti PD-(L)1 & Anti-VEGF The
Slide 9: 2024 Stock Performance and Financial Summary
2024 Stock Performance FINANCIAL SUMMARY 50-Day Moving Avg SMMT 2024 Stock Performance: 20.00 + 584%1 $435 Million in Financing in 2024 15.00 12/31/2024, cash & investments 10.00 balance $412 Million Current Debt: $0 5.00 ($31.8 Million in principal and interest was paid in Q4 2024) 0.00 738 Million
Slide 10: Financial Summary
Financial Summary (1) Excludes stock-based compensation Summit Confidential & Proprietary Information Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than 10 Do Not Copy or Distribute Presentation Summit Therapeutics Q4 & YE 2024 Earnings Call China
Slide 11: Schedule Reconciling Selected Non-GAAP Financial Measures
Schedule Reconciling Selected Non-GAAP Financial Measures Note 1: Stock-based compensation is a non-cash charge and costs calculated for this expense can vary year-over-year depending on the stock price of awards on the date of grant as well as the timing of compensation award arrangements. Summit C
Slide 12: Schedule Reconciling Selected Non-GAAP Financial Measures
Schedule Reconciling Selected Non-GAAP Financial Measures Note 1: Stock-based compensation is a non-cash charge and costs calculated for this expense can vary year-over-year depending on the stock price of awards on the date of grant as well as the timing of compensation award arrangements. Summit C
Slide 13: Summit Therapeutics Q4 & YE 2024 Earnings Call
Summit Therapeutics Q4 & YE 2024 Earnings Call February 24, 2025 9:00am ET